Login Register Cart 0
Generic placeholder image

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Proton Pump Inhibitors and Cognitive Health: Review on Unraveling the Dementia Connection and Co-morbid Risks

Author(s): Zuber Khan, Sidharth Mehan*, Mohd. Anas Saifi, Ghanshyam Das Gupta, Acharan S. Narula and Reni Kalfin

Volume 20, Issue 11, 2023

Published on: 28 February, 2024

Page: [739 - 757] Pages: 19

DOI: 10.2174/0115672050289946240223050737

Price: $65

Abstract

Dementia, an international health issue distinguished by the impairment of daily functioning due to cognitive decline, currently affects more than 55 million people worldwide, with the majority residing in low-income and middle-income countries. Globally, dementia entails significant economic burdens in 2019, amounting to a cost of 1.3 trillion US dollars. Informal caregivers devote considerable hours to providing care for those affected. Dementia imposes a greater caregiving and disability-adjusted life-year burden on women. A recent study has established a correlation between prolonged Proton Pump Inhibitor (PPI) usage and dementia, in addition to other neurodegenerative conditions. PPIs are frequently prescribed to treat peptic ulcers and GERD (gastroesophageal reflux disease) by decreasing stomach acid secretion. They alleviate acid-related symptoms through the inhibition of acid-secreting H+-K+ ATPase. In a number of observational studies, cognitive decline and dementia in the elderly have been linked to the use of PPIs. The precise mechanism underlying this relationship is unknown. These drugs might also alter the pH of brain cells, resulting in the accumulation of amyloid-beta (Aβ) peptides and the development of Alzheimer's disease (AD). Despite the compelling evidence supporting the association of PPIs with dementia, the results of studies remain inconsistent. The absence of a correlation between PPI use and cognitive decline in some studies emphasizes the need for additional research. Chronic PPI use can conceal underlying conditions, including cancer, celiac disease, vitamin B12 deficiency, and renal injury, highlighting dementia risk and the need for further investigations on cognitive health.

Next »
[1]
Gale, S.A.; Acar, D.; Daffner, K.R. Dementia. Am. J. Med., 2018, 131(10), 1161-1169.
[http://dx.doi.org/10.1016/j.amjmed.2018.01.022] [PMID: 29425707]
[2]
Dementia Available from: https://www.who.int/news-room/fact-sheets/detail/dementia#:~:text=Key%20facts,nearly%2010%20million%20new%20cases
[3]
GBD 2019 Collaborators. Global mortality from dementia: Application of a new method and results from the global burden of disease study 2019. Alzheimers Dement, 2021, 7(1), e12200.
[http://dx.doi.org/10.1002/trc2.12200]
[4]
Wimo, A.; Seeher, K.; Cataldi, R.; Cyhlarova, E.; Dielemann, J.L.; Frisell, O.; Guerchet, M.; Jönsson, L.; Malaha, A.K.; Nichols, E.; Pedroza, P.; Prince, M.; Knapp, M.; Dua, T. The worldwide costs of dementia in 2019. Alzheimers Dement., 2023, 19(7), 2865-2873. Advance online publication
[http://dx.doi.org/10.1002/alz.12901] [PMID: 36617519]
[5]
Mielke, M.M. Sex and gender differences in alzheimer’s disease dementia. Psychiatr. Times, 2018, 35(11), 14-17.
[PMID: 30820070]
[6]
Pourhadi, N.; Janbek, J.; Jensen-Dahm, C.; Gasse, C.; Laursen, T.M.; Waldemar, G. Proton pump inhibitors and dementia: A nationwide population-based study. Alzheimers Dement., 2023, alz.13477.
[http://dx.doi.org/10.1002/alz.13477] [PMID: 37795826]
[7]
Shin, J.M.; Sachs, G. Pharmacology of proton pump inhibitors. Curr. Gastroenterol. Rep., 2008, 10(6), 528-534.
[http://dx.doi.org/10.1007/s11894-008-0098-4] [PMID: 19006606]
[8]
Shanika, L.G.T.; Reynolds, A.; Pattison, S.; Braund, R. Proton pump inhibitor use: Systematic review of global trends and practices. Eur. J. Clin. Pharmacol., 2023, 79(9), 1159-1172.
[http://dx.doi.org/10.1007/s00228-023-03534-z] [PMID: 37420019]
[9]
Ahmed, A.; Clarke, J.O. Proton pump inhibitors (PPI). In: StatPearls; StatPearls Publishing, 2023.
[10]
Jaynes, M.; Kumar, A.B. The risks of long-term use of proton pump inhibitors: A critical review. Ther. Adv. Drug Saf., 2019, 10.
[http://dx.doi.org/10.1177/2042098618809927] [PMID: 31019676]
[11]
Li, M.; Luo, Z.; Yu, S.; Tang, Z. Proton pump inhibitor use and risk of dementia. Medicine, 2019, 98(7), e14422.
[http://dx.doi.org/10.1097/MD.0000000000014422] [PMID: 30762748]
[12]
Zhang, P.; Li, Z.; Chen, P.; Zhang, A.; Zeng, Y.; Zhang, X.; Huang, Q.; Liu, D.; Qi, S.; Mao, C. Regular proton pump inhibitor use and incident dementia: Population-based cohort study. BMC Med., 2022, 20(1), 271.
[http://dx.doi.org/10.1186/s12916-022-02478-y] [PMID: 36045363]
[13]
Cooksey, R.; Kennedy, J.; Dennis, M.S.; Escott-Price, V.; Lyons, R.A.; Seaborne, M.; Brophy, S. Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK. PLoS One, 2020, 15(9), e0237676.
[http://dx.doi.org/10.1371/journal.pone.0237676] [PMID: 32946449]
[14]
Masters, C.L.; Simms, G.; Weinman, N.A.; Multhaup, G.; McDonald, B.L.; Beyreuther, K. Amyloid plaque core protein in alzheimer disease and down syndrome. Proc. Natl. Acad. Sci. USA, 1985, 82(12), 4245-4249.
[http://dx.doi.org/10.1073/pnas.82.12.4245] [PMID: 3159021]
[15]
Papazoglou, A.; Arshaad, M.I.; Henseler, C.; Daubner, J.; Broich, K.; Haenisch, B.; Weiergräber, M. The janus-like association between proton pump inhibitors and dementia. Curr. Alzheimer Res., 2021, 18(6), 453-469.
[http://dx.doi.org/10.2174/1567205018666210929144740] [PMID: 34587884]
[16]
Ahn, J.S.; Eom, C.S.; Jeon, C.Y.; Park, S.M. Acid suppressive drugs and gastric cancer: A meta-analysis of observational studies. World J. Gastroenterol., 2013, 19(16), 2560-2568.
[http://dx.doi.org/10.3748/wjg.v19.i16.2560] [PMID: 23674860]
[17]
Tran-Duy, A.; Spaetgens, B.; Hoes, A. W.; de Wit, N. J.; Stehouwer, C. D. Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer: Systematic review and meta-analysis. Clin. Gastroenterol. Hepatol., 2016, 14(12), 1706-1719.
[http://dx.doi.org/10.1016/j.cgh.2016.05.018]
[18]
Boardman, H.F.; Delaney, B.C.; Haag, S. Partnership in optimizing management of reflux symptoms: A treatment algorithm for over-the-counter proton-pump inhibitors. Curr. Med. Res. Opin., 2015, 31(7), 1309-1318.
[http://dx.doi.org/10.1185/03007995.2015.1047745] [PMID: 25950642]
[19]
Lebwohl, B.; Spechler, S. J.; Wang, T. C.; Green, P. H.; Ludvigsson, J. F. Use of proton pump inhibitors and subsequent risk of celiac disease. Dig. Liver Dis., 2014, 46(1), 36-40.
[http://dx.doi.org/10.1016/j.dld.2013.08.128]
[20]
Jung, S.B.; Nagaraja, V.; Kapur, A.; Eslick, G.D. Association between vitamin B 12 deficiency and long-term use of acid-lowering agents: A systematic review and meta-analysis. Intern. Med. J., 2015, 45(4), 409-416.
[http://dx.doi.org/10.1111/imj.12697] [PMID: 25583062]
[21]
Moledina, D.G.; Perazella, M.A. PPIs and kidney disease: From AIN to CKD. J. Nephrol., 2016, 29(5), 611-616.
[http://dx.doi.org/10.1007/s40620-016-0309-2] [PMID: 27072818]
[22]
Gomm, W.; von Holt, K.; Thomé, F.; Broich, K.; Maier, W.; Fink, A.; Doblhammer, G.; Haenisch, B. Association of proton pump inhibitors with risk of dementia. JAMA Neurol., 2016, 73(4), 410-416.
[http://dx.doi.org/10.1001/jamaneurol.2015.4791] [PMID: 26882076]
[23]
Mumtaz, H.; Ghafoor, B.; Saghir, H.; Tariq, M.; Dahar, K.; Ali, S. H.; Waheed, S. T.; Syed, A. A. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol., 2022, 73(4), 410-416.
[http://dx.doi.org/10.1016/j.amsu.2022.104762]
[24]
Badiola, N.; Alcalde, V.; Pujol, A.; Münter, L.M.; Multhaup, G.; Lleó, A.; Coma, M.; Soler-López, M.; Aloy, P. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One, 2013, 8(3), e58837.
[http://dx.doi.org/10.1371/journal.pone.0058837] [PMID: 23520537]
[25]
Fallahzadeh, M.K.; Borhani Haghighi, A.; Namazi, M.R. Proton pump inhibitors: Predisposers to alzheimer disease? J. Clin. Pharm. Ther., 2010, 35(2), 125-126.
[http://dx.doi.org/10.1111/j.1365-2710.2009.01100.x] [PMID: 20456731]
[26]
Lam, J.R.; Schneider, J.L.; Zhao, W.; Corley, D.A. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA, 2013, 310(22), 2435-2442.
[http://dx.doi.org/10.1001/jama.2013.280490] [PMID: 24327038]
[27]
O’Brien, R.J.; Wong, P.C. Amyloid precursor protein processing and Alzheimer’s disease. Annu. Rev. Neurosci., 2011, 34(1), 185-204.
[http://dx.doi.org/10.1146/annurev-neuro-061010-113613] [PMID: 21456963]
[28]
Gray, S.L.; Walker, R.L.; Dublin, S.; Yu, O.; Aiello Bowles, E.J.; Anderson, M.L.; Crane, P.K.; Larson, E.B. Proton pump inhibitor use and dementia risk: Prospective population-based study. J. Am. Geriatr. Soc., 2018, 66(2), 247-253.
[http://dx.doi.org/10.1111/jgs.15073] [PMID: 29134629]
[29]
Hussain, S.; Singh, A.; Zameer, S.; Jamali, M.C.; Baxi, H.; Rahman, S.O.; Alam, M.; Altamish, M.; Singh, A.K.; Anil, D.; Hussain, M.S.; Ahmad, A.; Najmi, A.K. No association between proton pump inhibitor use and risk of dementia: Evidence from a meta-analysis. J. Gastroenterol. Hepatol., 2020, 35(1), 19-28.
[http://dx.doi.org/10.1111/jgh.14789] [PMID: 31334885]
[30]
Song, J.W.; Chung, K.C. Observational studies: Cohort and case-control studies. Plast. Reconstr. Surg., 2010, 126(6), 2234-2242.
[http://dx.doi.org/10.1097/PRS.0b013e3181f44abc] [PMID: 20697313]
[31]
Shi, J.; Norgeot, B. Learning causal effects from observational data in healthcare: A review and summary. Front. Med., 2022, 9, 864882.
[http://dx.doi.org/10.3389/fmed.2022.864882] [PMID: 35872797]
[32]
Chow, V.W.; Mattson, M.P.; Wong, P.C.; Gleichmann, M. An overview of APP processing enzymes and products. Neuromolecular Med., 2010, 12(1), 1-12.
[http://dx.doi.org/10.1007/s12017-009-8104-z] [PMID: 20232515]
[33]
Caetano, C.; Veloso, M.; Borda, S. Proton pump inhibitors and dementia: What association? Dement. Neuropsychol., 2023, 17, e20220048.
[http://dx.doi.org/10.1590/1980-5764-dn-2022-0048] [PMID: 37261259]
[34]
Maes, M.L.; Fixen, D.R.; Linnebur, S.A. Adverse effects of proton-pump inhibitor use in older adults: A review of the evidence. Ther. Adv. Drug Saf., 2017, 8(9), 273-297.
[http://dx.doi.org/10.1177/2042098617715381] [PMID: 28861211]
[35]
Ali Khan, M.; Howden, C.W. The role of proton pump inhibitors in the management of upper gastrointestinal disorders. Gastroenterol. Hepatol., 2018, 14(3), 169-175.
[PMID: 29928161]
[36]
Daneman, R.; Prat, A. The blood-brain barrier. Cold Spring Harb. Perspect. Biol., 2015, 7(1), a020412.
[http://dx.doi.org/10.1101/cshperspect.a020412] [PMID: 25561720]
[37]
Rojo, L.E.; Alzate-Morales, J.; Saavedra, I.N.; Davies, P.; Maccioni, R.B. Selective interaction of lansoprazole and astemizole with tau polymers: Potential new clinical use in diagnosis of alzheimer’s disease. J. Alzheimers Dis., 2010, 19(2), 573-589.
[http://dx.doi.org/10.3233/JAD-2010-1262] [PMID: 20110603]
[38]
Chimirri, S.; Aiello, R.; Mazzitello, C.; Mumoli, L.; Palleria, C.; Altomonte, M.; Citraro, R.; De Sarro, G. Vertigo/dizziness as a Drugs’ adverse reaction. J. Pharmacol. Pharmacother., 2013, 4(1_suppl)(Suppl. 1), S104-S109.
[http://dx.doi.org/10.4103/0976-500X.120969] [PMID: 24347974]
[39]
Yibirin, M.; De Oliveira, D.; Valera, R.; Plitt, A.E.; Lutgen, S. Adverse effects associated with proton pump inhibitor use. Cureus, 2021, 13(1), e12759.
[http://dx.doi.org/10.7759/cureus.12759] [PMID: 33614352]
[40]
Appleton, J. The gut-brain axis: Influence of microbiota on mood and mental health. Integr. Med., 2018, 17(4), 28-32.
[PMID: 31043907]
[41]
Bruno, G.; Zaccari, P.; Rocco, G.; Scalese, G.; Panetta, C.; Porowska, B.; Pontone, S.; Severi, C. Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified. World J. Gastroenterol., 2019, 25(22), 2706-2719.
[http://dx.doi.org/10.3748/wjg.v25.i22.2706] [PMID: 31235994]
[42]
Carabotti, M.; Scirocco, A.; Maselli, M.A.; Severi, C. The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems. Ann. Gastroenterol., 2015, 28(2), 203-209.
[PMID: 25830558]
[43]
Wijarnpreecha, K.; Thongprayoon, C.; Panjawatanan, P.; Ungprasert, P. Proton pump inhibitors and risk of dementia. Ann. Transl. Med., 2016, 4(12), 240.
[http://dx.doi.org/10.21037/atm.2016.06.14] [PMID: 27429966]
[44]
Fujimori, S. What are the effects of proton pump inhibitors on the small intestine? World J. Gastroenterol., 2015, 21(22), 6817-6819.
[http://dx.doi.org/10.3748/wjg.v21.i22.6817] [PMID: 26078557]
[45]
Vanderhoof, J. A.; Young, R. J. Etiology and pathogenesis of bacterial overgrowth. Clinical manifestations and diagnosis of bacterial overgrowth. Treatment of Bacterial Overgrowth., 2010, 18(1) Available from: http://www.uptodate.com.
[46]
Liang, S.; Xu, L.; Zhang, D.; Wu, Z. Effect of probiotics on small intestinal bacterial overgrowth in patients with gastric and colorectal cancer. Turk. J. Gastroenterol., 2016, 27(3), 227-232.
[http://dx.doi.org/10.5152/tjg.2016.15375]
[47]
Tang, W.H.W.; Kitai, T.; Hazen, S.L. Gut microbiota in cardiovascular health and disease. Circ. Res., 2017, 120(7), 1183-1196.
[http://dx.doi.org/10.1161/CIRCRESAHA.117.309715] [PMID: 28360349]
[48]
Saji, N.; Niida, S.; Murotani, K.; Hisada, T.; Tsuduki, T.; Sugimoto, T.; Kimura, A.; Toba, K.; Sakurai, T. Analysis of the relationship between the gut microbiome and dementia: A cross-sectional study conducted in Japan. Sci. Rep., 2019, 9(1), 1008.
[http://dx.doi.org/10.1038/s41598-018-38218-7] [PMID: 30700769]
[49]
Alkasir, R.; Li, J.; Li, X.; Jin, M.; Zhu, B. Human gut microbiota: The links with dementia development. Protein Cell, 2017, 8(2), 90-102.
[http://dx.doi.org/10.1007/s13238-016-0338-6] [PMID: 27866330]
[50]
Vogt, N.M.; Kerby, R.L.; Dill-McFarland, K.A.; Harding, S.J.; Merluzzi, A.P.; Johnson, S.C.; Carlsson, C.M.; Asthana, S.; Zetterberg, H.; Blennow, K.; Bendlin, B.B.; Rey, F.E. Gut microbiome alterations in alzheimer’s disease. Sci. Rep., 2017, 7(1), 13537.
[http://dx.doi.org/10.1038/s41598-017-13601-y] [PMID: 29051531]
[51]
Bures, J.; Cyrany, J.; Kohoutova, D.; Förstl, M.; Rejchrt, S.; Kvetina, J.; Vorisek, V.; Kopacova, M. Small intestinal bacterial overgrowth syndrome. World J. Gastroenterol., 2010, 16(24), 2978-2990.
[http://dx.doi.org/10.3748/wjg.v16.i24.2978] [PMID: 20572300]
[52]
Stadlbauer, V.; Engertsberger, L.; Komarova, I.; Feldbacher, N.; Leber, B.; Pichler, G.; Fink, N.; Scarpatetti, M.; Schippinger, W.; Schmidt, R.; Horvath, A. Dysbiosis, gut barrier dysfunction and inflammation in dementia: A pilot study. BMC Geriatr., 2020, 20(1), 248.
[http://dx.doi.org/10.1186/s12877-020-01644-2] [PMID: 32690030]
[53]
Belei, O.; Olariu, L.; Dobrescu, A.; Marcovici, T.; Marginean, O. Is it useful to administer probiotics together with proton pump inhibitors in children with gastroesophageal reflux? J. Neurogastroenterol. Motil., 2018, 24(1), 51-57.
[http://dx.doi.org/10.5056/jnm17059] [PMID: 29291607]
[54]
Imhann, F.; Bonder, M.J.; Vich Vila, A.; Fu, J.; Mujagic, Z.; Vork, L.; Tigchelaar, E.F.; Jankipersadsing, S.A.; Cenit, M.C.; Harmsen, H.J.M.; Dijkstra, G.; Franke, L.; Xavier, R.J.; Jonkers, D.; Wijmenga, C.; Weersma, R.K.; Zhernakova, A. Proton pump inhibitors affect the gut microbiome. Gut, 2016, 65(5), 740-748.
[http://dx.doi.org/10.1136/gutjnl-2015-310376] [PMID: 26657899]
[55]
Tsuda, A.; Suda, W.; Morita, H.; Takanashi, K.; Takagi, A.; Koga, Y.; Hattori, M. Influence of proton-pump inhibitors on the luminal microbiota in the gastrointestinal tract. Clin. Transl. Gastroenterol., 2015, 6(6), e89.
[http://dx.doi.org/10.1038/ctg.2015.20] [PMID: 26065717]
[56]
Vinke, P.; Wesselink, E.; van Orten-Luiten, W.; van Norren, K. The use of proton pump inhibitors may increase symptoms of muscle function loss in patients with chronic illnesses. Int. J. Mol. Sci., 2020, 21(1), 323.
[http://dx.doi.org/10.3390/ijms21010323] [PMID: 31947724]
[57]
Zhou, B.; Huang, Y.; Li, H.; Sun, W.; Liu, J. Proton-pump inhibitors and risk of fractures: An update meta-analysis. Osteoporos Int. , 2016, 27(1), 339-347.
[http://dx.doi.org/10.1007/s00198-015-3365-x]
[58]
Eusebi, L.H.; Rabitti, S.; Artesiani, M.L.; Gelli, D.; Montagnani, M.; Zagari, R.M.; Bazzoli, F. Proton pump inhibitors: Risks of long-term use. J. Gastroenterol. Hepatol., 2017, 32(7), 1295-1302.
[http://dx.doi.org/10.1111/jgh.13737] [PMID: 28092694]
[59]
Haastrup, P.F.; Thompson, W.; Søndergaard, J.; Jarbøl, D.E. Side effects of long-term proton pump inhibitor use: A review. Basic Clin. Pharmacol. Toxicol., 2018, 123(2), 114-121.
[http://dx.doi.org/10.1111/bcpt.13023] [PMID: 29658189]
[60]
Gröber, U.; Schmidt, J.; Kisters, K. Important drug-micronutrient interactions: A selection for clinical practice. Crit. Rev. Food Sci. Nutr., 2020, 60(2), 257-275.
[http://dx.doi.org/10.1080/10408398.2018.1522613] [PMID: 30580552]
[61]
Ito, T.; Jensen, R.T. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr. Gastroenterol. Rep., 2010, 12(6), 448-457.
[http://dx.doi.org/10.1007/s11894-010-0141-0] [PMID: 20882439]
[62]
Heidelbaugh, J.J. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Ther. Adv. Drug Saf., 2013, 4(3), 125-133.
[http://dx.doi.org/10.1177/2042098613482484] [PMID: 25083257]
[63]
Florentin, M.; Elisaf, M.S. Proton pump inhibitor-induced hypomagnesemia: A new challenge. World J. Nephrol., 2012, 1(6), 151-154.
[http://dx.doi.org/10.5527/wjn.v1.i6.151] [PMID: 24175253]
[64]
Semb, S.; Helgstrand, F.; Hjørne, F.; Bytzer, P. Persistent severe hypomagnesemia caused by proton pump inhibitor resolved after laparoscopic fundoplication. World J. Gastroenterol., 2017, 23(37), 6907-6910.
[http://dx.doi.org/10.3748/wjg.v23.i37.6907] [PMID: 29085234]
[65]
Gommers, L.M.M.; Hoenderop, J.G.J.; de Baaij, J.H.F. Mechanisms of proton pump inhibitor-induced hypomagnesemia. Acta Physiol., 2022, 235(4), e13846.
[http://dx.doi.org/10.1111/apha.13846] [PMID: 35652564]
[66]
Gerges, D.; Grohmann, N.; Trieu, V.; Brundage, W.; Sajisevi, M. Effect of PPIS on symptomatic hypocalcemia after thyroidectomy: A retrospective cohort study. Laryngoscope Investig. Otolaryngol., 2021, 6(1), 150-154.
[http://dx.doi.org/10.1002/lio2.515] [PMID: 33614944]
[67]
Losurdo, G.; Caccavo, N.L.B.; Indellicati, G.; Celiberto, F.; Ierardi, E.; Barone, M.; Di Leo, A. Effect of long-term proton pump inhibitor use on blood vitamins and minerals: A primary care setting study. J. Clin. Med., 2023, 12(8), 2910.
[http://dx.doi.org/10.3390/jcm12082910] [PMID: 37109245]
[68]
Cardoso, B.; Cominetti, C.; Cozzolino, S.M. Importance and management of micronutrient deficiencies in patients with Alzheimer’s disease. Clin. Interv. Aging, 2013, 8, 531-542.
[http://dx.doi.org/10.2147/CIA.S27983] [PMID: 23696698]
[69]
Penke, B.; Bogár, F.; Fülöp, L. β-amyloid and the pathomechanisms of alzheimer’s disease: A comprehensive view. Molecules, 2017, 22(10), 1692.
[http://dx.doi.org/10.3390/molecules22101692] [PMID: 28994715]
[70]
Shin, J.M.; Kim, N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J. Neurogastroenterol. Motil., 2013, 19(1), 25-35.
[http://dx.doi.org/10.5056/jnm.2013.19.1.25] [PMID: 23350044]
[71]
Zhang, H.J.; Zhang, X.H.; Liu, J.; Sun, L.N.; Shen, Y.W.; Zhou, C.; Zhang, H.W.; Xie, L.J.; Chen, J.; Liu, Y.; Wang, Y.Q. Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors. Pharmacol. Res., 2020, 152, 104606.
[http://dx.doi.org/10.1016/j.phrs.2019.104606] [PMID: 31846760]
[72]
van Driel, I.R.; Callaghan, J.M. Proton and potassium transport by H + /K + -ATPases. Clin. Exp. Pharmacol. Physiol., 1995, 22(12), 952-960.
[http://dx.doi.org/10.1111/j.1440-1681.1995.tb02332.x] [PMID: 8846517]
[73]
Modyanov, N.N.; Petrukhin, K.E.; Sverdlov, V.E.; Grishin, A.V.; Orlova, M.Y.; Kostina, M.B.; Makarevich, O.I.; Broude, N.E.; Monastyrskaya, G.S.; Sverdlov, E.D. The family of human Na,K-ATPase genes ATP1AL1 gene is transcriptionally competent and probably encodes the related ion transport ATPase. FEBS Lett., 1991, 278(1), 91-94.
[http://dx.doi.org/10.1016/0014-5793(91)80091-G] [PMID: 1847115]
[74]
Wang, D.; Hiesinger, P.R. The vesicular ATPase: A missing link between acidification and exocytosis. J. Cell Biol., 2013, 203(2), 171-173.
[http://dx.doi.org/10.1083/jcb.201309130] [PMID: 24165933]
[75]
Tabares, L.; Betz, B. Multiple functions of the vesicular proton pump in nerve terminals. Neuron, 2010, 68(6), 1020-1022.
[http://dx.doi.org/10.1016/j.neuron.2010.12.012] [PMID: 21172605]
[76]
Cheng, F.C.; Ho, Y.F.; Hung, L.C.; Chen, C.F.; Tsai, T.H. Determination and pharmacokinetic profile of omeprazole in rat blood, brain and bile by microdialysis and high-performance liquid chromatography. J. Chromatogr. A, 2002, 949(1-2), 35-42.
[http://dx.doi.org/10.1016/S0021-9673(01)01225-0] [PMID: 11999751]
[77]
Liang, J. F.; Chen, Y. T.; Fuh, J. L.; Li, S. Y.; Chen, T. J.; Tang, C. H.; Wang, S. J. Proton pump inhibitor-related headaches: A nationwide population-based case-crossover study in Taiwan. Cephalalgia, 2015, 35(3), 203-210.
[http://dx.doi.org/10.1177/0333102414535114]
[78]
Martin, R.M.; Dunn, N.R.; Freemantle, S.; Shakir, S. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: Cohort studies. Br. J. Clin. Pharmacol., 2000, 50(4), 366-372.
[http://dx.doi.org/10.1046/j.1365-2125.2000.00262.x] [PMID: 11012560]
[79]
Hanneken, A.M.; Babai, N.; Thoreson, W.B. Oral proton pump inhibitors disrupt horizontal cell-cone feedback and enhance visual hallucinations in macular degeneration patients. Invest. Ophthalmol. Vis. Sci., 2013, 54(2), 1485-1489.
[http://dx.doi.org/10.1167/iovs.12-11091] [PMID: 23341015]
[80]
Sandhu, D.S.; Fass, R. Current trends in the management of gastroesophageal reflux disease. Gut Liver, 2018, 12(1), 7-16.
[http://dx.doi.org/10.5009/gnl16615] [PMID: 28427116]
[81]
Duong, S.; Patel, T.; Chang, F. Dementia. Can. Pharm. J., 2017, 150(2), 118-129.
[http://dx.doi.org/10.1177/1715163517690745] [PMID: 28405256]
[82]
DeTure, M.A.; Dickson, D.W. The neuropathological diagnosis of alzheimer’s disease. Mol. Neurodegener., 2019, 14(1), 32.
[http://dx.doi.org/10.1186/s13024-019-0333-5] [PMID: 31375134]
[83]
Reitz, C. Genetic diagnosis and prognosis of alzheimer’s disease: Challenges and opportunities. Expert Rev. Mol. Diagn., 2015, 15(3), 339-348.
[http://dx.doi.org/10.1586/14737159.2015.1002469] [PMID: 25634383]
[84]
Venkat, P.; Chopp, M.; Chen, J. Models and mechanisms of vascular dementia. Exp. Neurol., 2015, 272, 97-108.
[http://dx.doi.org/10.1016/j.expneurol.2015.05.006] [PMID: 25987538]
[85]
Kalaria, R.N.; Akinyemi, R.; Ihara, M. Stroke injury, cognitive impairment and vascular dementia. Biochim. Biophys. Acta Mol. Basis Dis., 2016, 1862(5), 915-925.
[http://dx.doi.org/10.1016/j.bbadis.2016.01.015] [PMID: 26806700]
[86]
Outeiro, T.F.; Koss, D.J.; Erskine, D.; Walker, L.; Kurzawa-Akanbi, M.; Burn, D.; Donaghy, P.; Morris, C.; Taylor, J.P.; Thomas, A.; Attems, J.; McKeith, I. Dementia with Lewy bodies: An update and outlook. Mol. Neurodegener., 2019, 14(1), 5.
[http://dx.doi.org/10.1186/s13024-019-0306-8] [PMID: 30665447]
[87]
Zupancic, M.; Mahajan, A.; Handa, K. Dementia with lewy bodies: Diagnosis and management for primary care providers. Prim. Care Companion CNS Disord., 2011, 13(5), PCC.11r01190.
[http://dx.doi.org/10.4088/PCC.11r01190]
[88]
Mackenzie, I.R.A.; Neumann, M.; Bigio, E.H.; Cairns, N.J.; Alafuzoff, I.; Kril, J.; Kovacs, G.G.; Ghetti, B.; Halliday, G.; Holm, I.E.; Ince, P.G.; Kamphorst, W.; Revesz, T.; Rozemuller, A.J.M.; Kumar-Singh, S.; Akiyama, H.; Baborie, A.; Spina, S.; Dickson, D.W.; Trojanowski, J.Q.; Mann, D.M.A. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol., 2009, 117(1), 15-18.
[http://dx.doi.org/10.1007/s00401-008-0460-5] [PMID: 19015862]
[89]
Imfeld, P.; Bodmer, M.; Jick, S.S.; Meier, C.R. Proton pump inhibitor use and risk of developing alzheimer’s disease or vascular dementia: A case–control analysis. Drug Saf., 2018, 41(12), 1387-1396.
[http://dx.doi.org/10.1007/s40264-018-0704-9] [PMID: 30146658]
[90]
Taipale, H.; Tolppanen, A.M.; Tiihonen, M.; Tanskanen, A.; Tiihonen, J.; Hartikainen, S. No association between proton pump inhibitor use and risk of alzheimer’s disease. Am. J. Gastroenterol., 2017, 112(12), 1802-1808.
[http://dx.doi.org/10.1038/ajg.2017.196] [PMID: 28695906]
[91]
Batchelor, R.; Gilmartin, J.F.M.; Kemp, W.; Hopper, I.; Liew, D. Dementia, cognitive impairment and proton pump inhibitor therapy: A systematic review. J. Gastroenterol. Hepatol., 2017, 32(8), 1426-1435.
[http://dx.doi.org/10.1111/jgh.13750] [PMID: 28128476]
[92]
Ortiz-Guerrero, G.; Amador-Muñoz, D.; Calderón-Ospina, C.A.; López-Fuentes, D.; Nava Mesa, M.O. Proton pump inhibitors and dementia: Physiopathological mechanisms and clinical consequences. Neural Plast., 2018, 2018, 1-9.
[http://dx.doi.org/10.1155/2018/5257285] [PMID: 29755512]
[93]
Kinoshita, Y.; Ishimura, N.; Ishihara, S. Advantages and disadvantages of long-term proton pump inhibitor use. J. Neurogastroenterol. Motil., 2018, 24(2), 182-196.
[http://dx.doi.org/10.5056/jnm18001] [PMID: 29605975]
[94]
Katz, P.O.; Dunbar, K.B.; Schnoll-Sussman, F.H.; Greer, K.B.; Yadlapati, R.; Spechler, S.J. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am. J. Gastroenterol., 2022, 117(1), 27-56.
[http://dx.doi.org/10.14309/ajg.0000000000001538] [PMID: 34807007]
[95]
Guo, J.; Huang, X.; Dou, L.; Yan, M.; Shen, T.; Tang, W.; Li, J. Aging and aging-related diseases: From molecular mechanisms to interventions and treatments. Signal Transduct. Target. Ther., 2022, 7(1), 391.
[http://dx.doi.org/10.1038/s41392-022-01251-0] [PMID: 36522308]
[96]
Khan, Z.; Gupta, G.D.; Mehan, S. Cellular and molecular evidence of multiple sclerosis diagnosis and treatment challenges. J. Clin. Med., 2023, 12(13), 4274.
[http://dx.doi.org/10.3390/jcm12134274] [PMID: 37445309]
[97]
Pataky, M.W.; Young, W.F.; Nair, K.S. Hormonal and metabolic changes of aging and the influence of lifestyle modifications. Mayo Clin. Proc., 2021, 96(3), 788-814.
[http://dx.doi.org/10.1016/j.mayocp.2020.07.033] [PMID: 33673927]
[98]
Prajapati, A.; Mehan, S.; Khan, Z. The role of Smo-Shh/Gli signaling activation in the prevention of neurological and ageing disorders. Biogerontology, 2023, 24(4), 493-531.
[http://dx.doi.org/10.1007/s10522-023-10034-1] [PMID: 37097427]
[99]
Lochhead, P.; Hagan, K.; Joshi, A.D.; Khalili, H.; Nguyen, L.H.; Grodstein, F.; Chan, A.T. Association between proton pump inhibitor use and cognitive function in women. Gastroenterology, 2017, 153(4), 971-979.e4.
[http://dx.doi.org/10.1053/j.gastro.2017.06.061] [PMID: 28728964]
[100]
Bonomini, F.; Rodella, L.F.; Rezzani, R. Metabolic syndrome, aging and involvement of oxidative stress. Aging Dis., 2015, 6(2), 109-120.
[http://dx.doi.org/10.14336/AD.2014.0305] [PMID: 25821639]
[101]
Novotny, M.; Klimova, B.; Valis, M. PPI long term use: Risk of neurological adverse events? Front. Neurol., 2019, 9, 1142.
[http://dx.doi.org/10.3389/fneur.2018.01142] [PMID: 30671013]
[102]
Cristina, N.M.; Lucia, A. Nutrition and healthy aging: Prevention and treatment of gastrointestinal diseases. Nutrients, 2021, 13(12), 4337.
[http://dx.doi.org/10.3390/nu13124337] [PMID: 34959889]
[103]
Chiu, H.F.; Huang, Y.W.; Chang, C.C.; Yang, C.Y. Use of proton pump inhibitors increased the risk of hip fracture: A population-based case–control study. Pharmacoepidemiol. Drug Saf., 2010, 19(11), 1131-1136.
[http://dx.doi.org/10.1002/pds.2026] [PMID: 20872906]
[104]
Valderas, J.M.; Starfield, B.; Sibbald, B.; Salisbury, C.; Roland, M. Defining comorbidity: Implications for understanding health and health services. Ann. Fam. Med., 2009, 7(4), 357-363.
[http://dx.doi.org/10.1370/afm.983] [PMID: 19597174]
[105]
Khandeparkar, A.; Rataboli, P. A study of harmful drug–drug interactions due to polypharmacy in hospitalized patients in goa medical college. Perspect. Clin. Res., 2017, 8(4), 180-186.
[http://dx.doi.org/10.4103/picr.PICR_132_16] [PMID: 29109936]
[106]
Varghese, D.; Ishida, C.; Haseer Koya, H. Polypharmacy. In: StatPearls; StatPearls Publishing: Treasure Island (FL), 2022.
[PMID: 30422548]
[107]
Palleria, C.; Di Paolo, A.; Giofrè, C.; Caglioti, C.; Leuzzi, G.; Siniscalchi, A.; De Sarro, G.; Gallelli, L. Pharmacokinetic drug-drug interaction and their implication in clinical management. J. Res. Med. Sci., 2013, 18(7), 601-610.
[108]
Wedemeyer, R.S.; Blume, H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: An update. Drug Saf., 2014, 37(4), 201-211.
[http://dx.doi.org/10.1007/s40264-014-0144-0] [PMID: 24550106]
[109]
Raoul, J.L.; Moreau-Bachelard, C.; Gilabert, M.; Edeline, J.; Frénel, J.S. Drug–drug interactions with proton pump inhibitors in cancer patients: An underrecognized cause of treatment failure. ESMO Open, 2023, 8(1), 100880.
[http://dx.doi.org/10.1016/j.esmoop.2023.100880] [PMID: 36764092]
[110]
Ben Ghezala, I.; Luu, M.; Bardou, M. An update on drug–drug interactions associated with proton pump inhibitors. Expert Opin. Drug Metab. Toxicol., 2022, 18(5), 337-346.
[http://dx.doi.org/10.1080/17425255.2022.2098107] [PMID: 35787720]
[111]
Błeszyńska, E.; Wierucki, Ł.; Zdrojewski, T.; Renke, M. Pharmacological interactions in the elderly. Medicina, 2020, 56(7), 320.
[http://dx.doi.org/10.3390/medicina56070320] [PMID: 32605319]
[112]
Maxwell, S.R.J. Rational prescribing: The principles of drug selection. Clin. Med., 2016, 16(5), 459-464.
[http://dx.doi.org/10.7861/clinmedicine.16-5-459] [PMID: 27697811]
[113]
Garfinkel, D. Poly-de-prescribing to treat polypharmacy: Efficacy and safety. Ther. Adv. Drug Saf., 2018, 9(1), 25-43.
[http://dx.doi.org/10.1177/2042098617736192] [PMID: 29318004]
[114]
Chen, T.K.; Knicely, D.H.; Grams, M.E. Chronic kidney disease diagnosis and management. JAMA, 2019, 322(13), 1294-1304.
[http://dx.doi.org/10.1001/jama.2019.14745] [PMID: 31573641]
[115]
Kang, J.H.E.; Kang, J.Y. Lifestyle measures in the management of gastro-oesophageal reflux disease: Clinical and pathophysiological considerations. Ther. Adv. Chronic Dis., 2015, 6(2), 51-64.
[http://dx.doi.org/10.1177/2040622315569501] [PMID: 25729556]
[116]
Mejia, A.; Kraft, W.K. Acid peptic diseases: Pharmacological approach to treatment. Expert Rev. Clin. Pharmacol., 2009, 2(3), 295-314.
[http://dx.doi.org/10.1586/ecp.09.8] [PMID: 21822447]
[117]
Kahrilas, P.J.; Boeckxstaens, G.; Smout, A.J.P.M. Management of the patient with incomplete response to PPI therapy. Best Pract. Res. Clin. Gastroenterol., 2013, 27(3), 401-414.
[http://dx.doi.org/10.1016/j.bpg.2013.06.005] [PMID: 23998978]
[118]
Farrell, B.; Pottie, K.; Thompson, W.; Boghossian, T.; Pizzola, L.; Rashid, F.J.; Rojas-Fernandez, C.; Walsh, K.; Welch, V.; Moayyedi, P. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can. Fam. Physician, 2017, 63(5), 354-364.
[PMID: 28500192]
[119]
Gumbar, S.; Bhardwaj, S.; Mehan, S.; Khan, Z.; Narula, A.S.; Kalfin, R.; Tabrez, S.; Zughaibi, T.A.; Wasi, S. Renal mitochondrial restoration by gymnemic acid in gentamicin-mediated experimental nephrotoxicity: evidence from serum, kidney and histopathological alterations. Front. Pharmacol., 2023, 14, 1218506.
[http://dx.doi.org/10.3389/fphar.2023.1218506] [PMID: 37521462]
[120]
Jimmy, B.; Jose, J. Patient medication adherence: Measures in daily practice. Oman Med. J., 2011, 26(3), 155-159.
[http://dx.doi.org/10.5001/omj.2011.38] [PMID: 22043406]
[121]
Douwes, R.M.; Gomes-Neto, A.W.; Schutten, J.C.; van den Berg, E.; de Borst, M.H.; Berger, S.P.; Touw, D.J.; Hak, E.; Blokzijl, H.; Navis, G.; Bakker, S.J.L. Proton-pump inhibitors and hypomagnesaemia in kidney transplant recipients. J. Clin. Med., 2019, 8(12), 2162.
[http://dx.doi.org/10.3390/jcm8122162] [PMID: 31817776]
[122]
Scarpignato, C.; Gatta, L.; Zullo, A.; Blandizzi, C. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Med., 2016, 14(1), 179.
[http://dx.doi.org/10.1186/s12916-016-0718-z] [PMID: 27825371]
[123]
Miller, J.W. Proton pump inhibitors, H2-receptor antagonists, metformin, and vitamin B-12 deficiency: Clinical implications. Adv. Nutr., 2018, 9(4), 511S-518S.
[http://dx.doi.org/10.1093/advances/nmy023] [PMID: 30032223]
[124]
Torres-Bondia, F.; Dakterzada, F.; Galván, L.; Buti, M.; Besanson, G.; Gill, E.; Buil, R.; de Batlle, J.; Piñol-Ripoll, G. Proton pump inhibitors and the risk of alzheimer’s disease and non-alzheimer’s dementias. Sci. Rep., 2020, 10(1), 21046.
[http://dx.doi.org/10.1038/s41598-020-78199-0] [PMID: 33273636]
[125]
Park, S.K.; Baek, Y.H.; Pratt, N.; Kalisch Ellett, L.; Shin, J.Y. The uncertainty of the association between proton pump inhibitor use and the risk of dementia: Prescription sequence symmetry analysis using a korean healthcare database between 2002 and 2013. Drug Saf., 2018, 41(6), 615-624.
[http://dx.doi.org/10.1007/s40264-018-0638-2] [PMID: 29397553]
[126]
Chen, L.Y.; Lin, H.J.; Wu, W.T.; Chen, Y.C.; Chen, C.L.; Kao, J.; You, S.L.; Chou, Y.C.; Sun, C.A. Clinical use of acid suppressants and risk of dementia in the elderly: A pharmaco-epidemiological cohort study. Int. J. Environ. Res. Public Health, 2020, 17(21), 8271.
[http://dx.doi.org/10.3390/ijerph17218271] [PMID: 33182362]
[127]
Welu, J.; Metzger, J.; Bebensee, S.; Ahrendt, A.; Vasek, M. Proton pump inhibitor use and risk of dementia in the veteran population. Federal practitioner: For the health care professionals of the VA. DoD, and PHS, 2019, 36(Suppl. 4), S27-S31.
[128]
Huang, S.T.; Tseng, L.Y.; Chen, L.K.; Peng, L.N.; Hsiao, F.Y. Does long-term proton pump inhibitor use increase risk of dementia? not really! results of the group-based trajectory analysis. Clin. Pharmacol. Ther., 2019, 106(3), 616-622.
[http://dx.doi.org/10.1002/cpt.1430] [PMID: 30861103]
[129]
Moayyedi, P.; Eikelboom, J.W.; Bosch, J.; Connolly, S.J.; Dyal, L.; Shestakovska, O.; Leong, D.; Anand, S.S.; Störk, S.; Branch, K.R.H.; Bhatt, D.L.; Verhamme, P.B.; O’Donnell, M.; Maggioni, A.P.; Lonn, E.M.; Piegas, L.S.; Ertl, G.; Keltai, M.; Bruns, N.C.; Muehlhofer, E.; Dagenais, G.R.; Kim, J.H.; Hori, M.; Steg, P.G.; Hart, R.G.; Diaz, R.; Alings, M.; Widimsky, P.; Avezum, A.; Probstfield, J.; Zhu, J.; Liang, Y.; Lopez-Jaramillo, P.; Kakkar, A.K.; Parkhomenko, A.N.; Ryden, L.; Pogosova, N.; Dans, A.L.; Lanas, F.; Commerford, P.J.; Torp-Pedersen, C.; Guzik, T.J.; Vinereanu, D.; Tonkin, A.M.; Lewis, B.S.; Felix, C.; Yusoff, K.; Metsarinne, K.P.; Fox, K.A.A.; Yusuf, S. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology, 2019, 157(3), 682-691.e2.
[http://dx.doi.org/10.1053/j.gastro.2019.05.056] [PMID: 31152740]
[130]
Wod, M.; Hallas, J.; Andersen, K.; García Rodríguez, L. A.; Christensen, K.; Gaist, D. Lack of association between proton pump inhibitor use and cognitive decline. Clin. Gastroenterol. Hepatol., 2018, 16(5), 681-689.
[http://dx.doi.org/10.1016/j.cgh.2018.01.034]
[131]
Goldstein, F.C.; Steenland, K.; Zhao, L.; Wharton, W.; Levey, A.I.; Hajjar, I. Proton pump inhibitors and risk of mild cognitive impairment and dementia. J. Am. Geriatr. Soc., 2017, 65(9), 1969-1974.
[http://dx.doi.org/10.1111/jgs.14956] [PMID: 28590010]
[132]
Khan, M.A.; Yuan, Y.; Iqbal, U.; Kamal, S.; Khan, M.; Khan, Z.; Lee, W.M.; Howden, C.W. No association linking short-term proton pump inhibitor use to dementia: Systematic review and meta-analysis of observational studies. Am. J. Gastroenterol., 2020, 115(5), 671-678.
[http://dx.doi.org/10.14309/ajg.0000000000000500] [PMID: 31895707]
[133]
Sigterman, K.E.; van Pinxteren, B.; Bonis, P.A.; Lau, J.; Numans, M.E. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Libr., 2013, 2013(5), CD002095.
[http://dx.doi.org/10.1002/14651858.CD002095.pub5] [PMID: 23728637]
[134]
Adlimoghaddam, A.; Neuendorff, M.; Roy, B.; Albensi, B.C. A review of clinical treatment considerations of donepezil in severe alzheimer’s disease. CNS Neurosci. Ther., 2018, 24(10), 876-888.
[http://dx.doi.org/10.1111/cns.13035] [PMID: 30058285]
[135]
Cacabelos, R. Donepezil in alzheimer’s disease: From conventional trials to pharmacogenetics. Neuropsychiatr. Dis. Treat., 2007, 3(3), 303-333.
[PMID: 19300564]
[136]
Khoury, R.; Rajamanickam, J.; Grossberg, G.T. An update on the safety of current therapies for Alzheimer’s disease: Focus on rivastigmine. Ther. Adv. Drug Saf., 2018, 9(3), 171-178.
[http://dx.doi.org/10.1177/2042098617750555] [PMID: 29492246]
[137]
Birks, J.S.; Chong, L.Y.; Grimley Evans, J. Rivastigmine for alzheimer’s disease. Cochrane Libr., 2015, 9(9), CD001191.
[http://dx.doi.org/10.1002/14651858.CD001191.pub4] [PMID: 26393402]
[138]
Aronson, S.; Van Baelen, B.; Kavanagh, S.; Schwalen, S. Optimal dosing of galantamine in patients with mild or moderate alzheimer’s disease: Post Hoc analysis of a randomized, double-blind, placebo-controlled trial. Drugs Aging, 2009, 26(3), 231-239.
[http://dx.doi.org/10.2165/00002512-200926030-00004] [PMID: 19358618]
[139]
Prvulovic, D.; Hampel, H.; Pantel, J. Galantamine for alzheimer’s disease. Expert Opin. Drug Metab. Toxicol., 2010, 6(3), 345-354.
[http://dx.doi.org/10.1517/17425251003592137] [PMID: 20113148]
[140]
Emre, M.; Tsolaki, M.; Bonuccelli, U.; Destée, A.; Tolosa, E.; Kutzelnigg, A.; Ceballos-Baumann, A.; Zdravkovic, S.; Bladström, A.; Jones, R. Memantine for patients with parkinson’s disease dementia or dementia with Lewy bodies: A randomised, double-blind, placebo-controlled trial. Lancet Neurol., 2010, 9(10), 969-977.
[http://dx.doi.org/10.1016/S1474-4422(10)70194-0] [PMID: 20729148]
[141]
Boot, B.P.; McDade, E.M.; McGinnis, S.M.; Boeve, B.F. Treatment of dementia with lewy bodies. Curr. Treat. Options Neurol., 2013, 15(6), 738-764.
[http://dx.doi.org/10.1007/s11940-013-0261-6] [PMID: 24222315]
[142]
McShane, R.; Westby, M.J.; Roberts, E.; Minakaran, N.; Schneider, L.; Farrimond, L.E.; Maayan, N.; Ware, J.; Debarros, J. Memantine for dementia. Cochrane Libr., 2019, 3(3), CD003154.
[http://dx.doi.org/10.1002/14651858.CD003154.pub6] [PMID: 30891742]
[143]
Hudson, S.A.; Tabet, N. Acetyl-l-carnitine for dementia. Cochrane Libr., 2003, 2003(2), CD003158.
[http://dx.doi.org/10.1002/14651858.CD003158] [PMID: 12804452]
[144]
Wang, S.M.; Han, C.; Lee, S.J.; Patkar, A.A.; Masand, P.S.; Pae, C.U. A review of current evidence for acetyl-l-carnitine in the treatment of depression. J. Psychiatr. Res., 2014, 53, 30-37.
[http://dx.doi.org/10.1016/j.jpsychires.2014.02.005] [PMID: 24607292]
[145]
Pennisi, M.; Lanza, G.; Cantone, M.; D’Amico, E.; Fisicaro, F.; Puglisi, V.; Vinciguerra, L.; Bella, R.; Vicari, E.; Malaguarnera, G. Acetyl-L-carnitine in dementia and other cognitive disorders: A critical update. Nutrients, 2020, 12(5), 1389.
[http://dx.doi.org/10.3390/nu12051389] [PMID: 32408706]
[146]
Xing, S. H.; Zhu, C. X.; Zhang, R.; An, L. Huperzine a in the treatment of alzheimer's disease and vascular dementia: A meta-analysis. Evid. Based Complement. Altern. Med., 2014, 363985.
[http://dx.doi.org/10.1155/2014/363985]
[147]
Hao, Z.; Liu, M.; Liu, Z.; Lu, D.H. Huperzine A for vascular dementia. Cochrane Libr., 2009, (2), CD007365.
[http://dx.doi.org/10.1002/14651858.CD007365.pub2] [PMID: 19370686]
[148]
Tariot, P. N.; Schneider, L.; Katz, I. R.; Mintzer, J. E.; Street, J.; Copenhaver, M.; Williams-Hughes, C. Quetiapine treatment of psychosis associated with dementia: A double-blind, randomized, placebo-controlled clinical trial. Am. J. Geriatr. Psychiatr., 2006, 14(9), 767-776.
[http://dx.doi.org/10.1097/01.JGP.0000196628.12010.35]
[149]
Zhong, K.; Tariot, P.; Mintzer, J.; Minkwitz, M.; Devine, N. Quetiapine to treat agitation in dementia: A randomized, double-blind, placebo-controlled study. Curr. Alzheimer Res., 2007, 4(1), 81-93.
[http://dx.doi.org/10.2174/156720507779939805] [PMID: 17316169]
[150]
Beshir, S.A.; Aadithsoorya, A.M.; Parveen, A.; Goh, S.S.L.; Hussain, N.; Menon, V.B. Aducanumab therapy to treat alzheimer’s disease: A narrative review. Int. J. Alzheimers Dis., 2022, 2022, 1-10.
[http://dx.doi.org/10.1155/2022/9343514] [PMID: 35308835]
[151]
Ferrero, J.; Williams, L.; Stella, H.; Leitermann, K.; Mikulskis, A.; O’Gorman, J.; Sevigny, J. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer’s disease. Alzheimers Dement., 2016, 2(3), 169-176.
[http://dx.doi.org/10.1016/j.trci.2016.06.002] [PMID: 29067304]
[152]
van Dyck, C.H.; Swanson, C.J.; Aisen, P.; Bateman, R.J.; Chen, C.; Gee, M.; Kanekiyo, M.; Li, D.; Reyderman, L.; Cohen, S.; Froelich, L.; Katayama, S.; Sabbagh, M.; Vellas, B.; Watson, D.; Dhadda, S.; Irizarry, M.; Kramer, L.D.; Iwatsubo, T. Lecanemab in early alzheimer’s disease. N. Engl. J. Med., 2023, 388(1), 9-21.
[http://dx.doi.org/10.1056/NEJMoa2212948] [PMID: 36449413]
[153]
McDade, E.; Cummings, J.L.; Dhadda, S.; Swanson, C.J.; Reyderman, L.; Kanekiyo, M.; Koyama, A.; Irizarry, M.; Kramer, L.D.; Bateman, R.J. Lecanemab in patients with early Alzheimer’s disease: Detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res. Ther., 2022, 14(1), 191.
[http://dx.doi.org/10.1186/s13195-022-01124-2] [PMID: 36544184]
[154]
Grossberg, G. T.; Kohegyi, E.; Mergel, V.; Josiassen, M. K.; Meulien, D.; Hobart, M.; Slomkowski, M.; Baker, R. A.; McQuade, R. D.; Cummings, J. L. Efficacy and safety of brexpiprazole for the treatment of agitation in alzheimer's dementia: Two 12-week, randomized, double-blind, placebo-controlled trials. Am. J. Geriatr. Psychiatr., 2020, 28(4), 383-400.
[http://dx.doi.org/10.1016/j.jagp.2019.09.009]
[155]
Stummer, L.; Markovic, M.; Maroney, M. Brexpiprazole in the treatment of schizophrenia and agitation in alzheimer’s disease. Neurodegener. Dis. Manag., 2020, 10(4), 205-217.
[http://dx.doi.org/10.2217/nmt-2020-0013] [PMID: 32618483]
[156]
Hanazawa, T.; Kamijo, Y. Effect of suvorexant on nocturnal delirium in elderly patients with alzheimer's disease: A case-series study. Clin. Psychopharmacol. Neurosci., 2019, 17(4), 547-550.
[http://dx.doi.org/10.9758/cpn.2019.17.4.547]
[157]
Herring, W.J.; Ceesay, P.; Snyder, E.; Bliwise, D.; Budd, K.; Hutzelmann, J.; Stevens, J.; Lines, C.; Michelson, D. Polysomnographic assessment of suvorexant in patients with probable alzheimer’s disease dementia and insomnia: A randomized trial. Alzheimers Dement., 2020, 16(3), 541-551.
[http://dx.doi.org/10.1002/alz.12035] [PMID: 31944580]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy